
FDA grant ODD for hyperammonemia in inborn errors of metabolism
Versantis’ lead product candidate VS-01 has been has granted orphan drug designation (ODD) by the Food and Drug Administration (FDA) for the treatment of hyperammonemia (HA) in inborn errors of metabolism (IEM). “This orphan drug designation from the FDA validates the scientific rationale of VS-01 in a… Read More














